Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications
- Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recovery
- This has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effective
- DehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertension
- The recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD space
- Lexaria is excited about the expansion and anticipates additional growth in its technology’s adoption as time progresses
For a long time, the medical industry has sought ways to improve patient health by enhancing the delivery of therapeutic drugs to target sites. An especially critical problem researchers in this sector have encountered is the limited solubility of the molecules intended for absorption.
It is estimated that approximately 90% of preclinical drug candidates are low-solubility compounds. This presents a challenge regarding the compounds’ bioavailability and effectiveness of the drugs. The problem has led researchers to explore various drug delivery technologies, some of which have shown promise while others have failed (https://nnw.fm/9zhjj ).
Lexaria Bioscience (NASDAQ: LEXX) has come forth with what they are confident is the best solution, their patented DehydraTECH(TM) technology. It has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. In addition, studies repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery.
DehydraTECH application areas tested so far include CBD for hypertension, oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases and PDE5 inhibitors. A new sector showing promise is the CBD industry, valued at $4.1 billion in 2022 and projected to hit $111.8 billion by 2030 (https://nnw.fm/5mzZI ).
DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a DehydraTECH licensee, into Europe, Japan, and South Africa (https://nnw.fm/zwj03 ).
Boldt Runners Corporation owns the Cannadips Brand, whose Cannadips CBD dip pouch is the leading CBD pouch brand in the United States. As a tobacco-free, nicotine-free dip alternative, this product offers an effective way to get the benefits of CBD by leveraging Lexaria’s DehydraTECH delivery technology. The product is sold in over 6,500 stores across the United States, and its expansion beyond the country is a major step, not just for Boldt Runners but also for Lexaria.
As Lexaria’s list of licensees continues to grow, more consumers will benefit from the DehydraTECH technology. The company is confident that, as the adoption of this technology grows, it will not only help its partners offer clients superior performance and experiences, but also ramp up shareholder value.
“Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” noted Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”).
“We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come,” he added.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recovery
- This has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effective
- DehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertension
- The recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD space
- Lexaria is excited about the expansion and anticipates additional growth in its technology’s adoption as time progresses
For a long time, the medical industry has sought ways to improve patient health by enhancing the delivery of therapeutic drugs to target sites. An especially critical problem researchers in this sector have encountered is the limited solubility of the molecules intended for absorption.
It is estimated that approximately 90% of preclinical drug candidates are low-solubility compounds. This presents a challenge regarding the compounds’ bioavailability and effectiveness of the drugs. The problem has led researchers to explore various drug delivery technologies, some of which have shown promise while others have failed (https://nnw.fm/9zhjj ).
Lexaria Bioscience (NASDAQ: LEXX) has come forth with what they are confident is the best solution, their patented DehydraTECH(TM) technology. It has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. In addition, studies repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery.
DehydraTECH application areas tested so far include CBD for hypertension, oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases and PDE5 inhibitors. A new sector showing promise is the CBD industry, valued at $4.1 billion in 2022 and projected to hit $111.8 billion by 2030 (https://nnw.fm/5mzZI ).
DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a DehydraTECH licensee, into Europe, Japan, and South Africa (https://nnw.fm/zwj03 ).
Boldt Runners Corporation owns the Cannadips Brand, whose Cannadips CBD dip pouch is the leading CBD pouch brand in the United States. As a tobacco-free, nicotine-free dip alternative, this product offers an effective way to get the benefits of CBD by leveraging Lexaria’s DehydraTECH delivery technology. The product is sold in over 6,500 stores across the United States, and its expansion beyond the country is a major step, not just for Boldt Runners but also for Lexaria.
As Lexaria’s list of licensees continues to grow, more consumers will benefit from the DehydraTECH technology. The company is confident that, as the adoption of this technology grows, it will not only help its partners offer clients superior performance and experiences, but also ramp up shareholder value.
“Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” noted Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”).
“We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come,” he added.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
